The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
The U.S. Federal Trade Commission (FTC) announced last week that it is, for the second time, disputing hundreds of “junk” ...
U.S. Senator Bernie Sanders commended the Biden administration for its efforts to combat pharmaceutical companies’ ...
In an attempt to curb inaccurate patent listings in the Food and Drug Administration’s “Orange Book,” a list of drugs the FDA has deemed safe and effective, the Federal Trade Commission has ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining to 20 different brand-name treatments for ...
The FTC recently announced that it has sent another round of letters disputing additional patent listings in the FDA’s Orange Book. With this latest action, the FTC has now challenged hundreds of ...
WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss ...
“The FTC acts as if the agency is being perfectly clear on what it’s subjecting companies to, but there’s never been a conversation around what it means for a patent to claim a drug product.” ...
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ...
FTC released its Fiscal Year 2023 Annual Report outlining the agency’s work to protect consumers and promote competition.
Shortly after Novo Holdings’ parent company elected to resubmit paperwork around the investment firm’s proposed $16.5 billion buyout of CDMO giant Catalent, the U.S. Federal Trade Commission ...